9th Conference on Retroviruses and Opportunistic Infections Seattle, Washington - February 24 -February 28, 2002

Conf Retroviruses Opportunistic Infect 2002 Feb 24-28;9:abstract no. 4
B. Gazzard¹, A. Pozniak¹, K. Arasteh², S. Staszewski³, W. Rozenbaum⁴, P. Yeni⁵, G. van't Klooster⁶, K. De Dier⁶, M. Peeters⁶, M. P. de Béthune⁶, N. Graham⁷, and R. Pauwels^6
1Chelsea and Westminster Hosp., London, UK; ²Epimed GmbH c/o Auguste-Viktoria Klinikum, Berlin, Germany; ³Universitaetsklinikum, Frankfurt, Germany; ⁴Hop. Rothschild, Paris, France; ⁵Hop. Bichat-Claude Bernard, Paris, France; ⁶Tibotec-Virco NV, Mechelen, Belgium; and ⁷Tibotec-Virco, Durham, NC

BACKGROUND OF STUDY: TMC125 (R165335) is a novel, next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with equipotent in vitro activity (EC₅₀ = 1-10 nM) against wild-type HIV-1 and NNRTI-resistant variants encoding L100I, K103N, Y181C, Y188L and/or G190A/S mutations.

OBJECTIVE: To evaluate the antiviral activity of TMC125 in antiretroviral experienced patients infected with NNRTI-resistant virus who fail on an NNRTI-containing regimen.

DESIGN: Open Phase IIA study. Sixteen HIV-1-infected male individuals, failing an efavirenz (EFV) or nevirapine (NVP) containing therapy and presenting with documented resistance to EFV (>10 fold change in susceptibility assessed by VirtualPhenotype™ and/or Antivirogram®), were eligible for inclusion. Patients received 900 mg TMC125 BID for 7 days, substituting the failing NNRTI, while they continued taking their NRTIs (unchanged). After day 7, treatment with TMC125 was terminated; treatment was continued with an investigator-selected ART.

RESULTS: Sixteen patients were enrolled, with the following median baseline characteristics: age: 38 years; CD4 cell count: 389 cells/µL; HIV-1 RNA: 10,753 copies/ml. The median fold change in EC₅₀ (Antivirogram®) to EFV at screening was 111 (range: 16-659), while fold changes in EC₅₀ (Antivirogram®) to TMC125 ranged between 0.5 and 8.3 (median: 2.6). All patients had >35 fold decreased sensitivity to NVP. NNRTI mutations found included L100I, K103N, Y181C, Y188L, G190A/S, with 12 patients having multiple NNRTI mutations. All patients had NRTI mutations and all but one had protease mutations. One patient was withdrawn on day 5 because of non-compliance. The median (min; max) changes in log₁₀viral load from baseline were:

After 7 days of treatment, the median decrease in viral load was 0.9 log₁₀from baseline. Viral load continued to decrease on day 8. Twelve patients (75%) had a decrease in viral load of at least 0.5 log₁₀; in 7 patients (44%) a decrease greater than 1 log₁₀ was observed. There was no relationship between response and geno/phenotype. Eleven patients reported Grade 1 adverse events. Diarrhoea (n=5), and headache (n=4) were most common.

CONCLUSION: TMC125, a next-generation NNRTI, administered at 900 mg BID for 7 days in treatment-experienced patients with highly NNRTI-resistant virus and currently failing on an NNRTI-containing regimen demonstrates significant antiviral potency and is well tolerated.

020224
4

Copyright © 2002 - Foundation for Retrovirology and Human Health. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed (AIDSLINE) from National Library of Medicine.